GLPwatch
Bydureon vs Saxenda
Drug comparison
Last updated 2026-05-28 15:46 UTCBydureon (exenatide by AstraZeneca) is a once-weekly injection for type 2 diabetes, while Saxenda (liraglutide by Novo Nordisk) is a daily injection approved for weight management in obesity. Both are given under the skin, but Bydureon uses exenatide and Saxenda uses liraglutide as their active ingredients.
AI summary of the sources below.
| Bydureon | Saxenda | |
|---|---|---|
| Active ingredient | exenatide | liraglutide |
| Manufacturer | astrazeneca | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | obesity |
| Label updated | — | 2026-02-25 |